Detect the invisible in an instant

The Most Accurate, Real-time Skin Cancer Diagnostic

Product description

What is Spectra-Scope® ?

Spectra-Scope® offers the most accurate and rapid risk assessment in skin cancer detection for basal cell carcinoma (BCC),
squamous cell instantaneous carcinoma (SCC) and malignant melanoma.

Spectra-Scope® provides unprecedented instantaneous skin lesion analysis with superior diagnostic accuracy.
The combination of laser induced plasma spectroscopy (LIPS) and a proprietary (Artificial Intelligence) AI-based diagnostic algorithm allow for unrivaled clinical accuracy in both sensitivity and specificity.

Spectra-Scope® provides additional accuracy, efficiency, and verification for better clinical decisions prior to any excision.
Physicians can use Spectra-Scope® to quickly scan challenging lesions to have an instantaneous secondary verification to help support clinical decisions.

Visual examination of skin lesions
Specially-trained physicians diagnose lesions based on a published set of criteria. Any lesions that are challenging to classify are typically excised and sent out for biopsy for confirmation.

Increase early diagnosis accuracy
Lesions that are secondarily verified by Spectra-Scope® have a higher chance of being correctly diagnosed as positive through biopsy.

Improve efficiency
The detailed visual examination of challenging lesions to determine diagnosis and treatment is time consuming. Spectra-Scope® can scan these lesions and provide verification in a matter of seconds without compromising clinical accuracy.

Reduce the number of unnecessary biopsies

Challenging lesions can be verified by Spectra-Scope® before being sent for biopsy, avoiding unnecessary biopsies of benign lesions.

Biochemical analysis of a skin lesion in just a few nanoseconds
The Laser Induced Plasma Spectroscopy (LIPS) of Spectra-Scope® uses a laser irradiation of a few nanoseconds to induce micro plasma on the skin tissue without any tissue damage. The micro plasma emissions created by the laser instantly reveals the biochemical information of the skin tissue at the molecular and atomic level.

Deep Learning-based skin cancer detection algorithm for unrivaled accuracy
Each emission spectrum of skin tissue acquired using LIPS has over 4000 parameters, providing detailed biochemical information of the tissue. The spectral patterns of the skin tissue’s emission spectra vary under different medical conditions. Spectra-Scope®’s deep learning-based proprietary diagnostic algorithm differentiates the conditions of BCC, SCC and malignant melanoma with high accuracy. The diagnostic algorithm was constructed by a deep neural network trained with a total 5302 emission spectra.

Quick, easy and reliable procedure
Spectra-Scope® is quick, reliable and easy to use. To evaluate the degree of atypia in a lesion, measurements are performed on a reference area close to the lesion, as well as on the lesion itself. The procedure takes only a second, and the LIPS score and the corresponding clinical predictive value of the lesion are displayed within a few seconds.

Unprecedented accuracy in sensitivity (95%) and specificity (87%) proven in worldwide clinical studies
Spectra-Scope’s® diagnostic accuracy has been proven by worldwide clinical studies in the United States and Australia. A series of clinical studies were used to evaluate the effectiveness and safety of Spectra-Scope®. A deep learning-based algorithm was used to create a robust database of information, leading to ground-breaking accuracy in both sensitivity and specificity. The identification of skin cancers (BCC, SCC and malignant melanoma) vs benign lesions were accurately diagnosed with 94.9% sensitivity and 86.9% specificity.

Easy to interpret clinical results
The LIPS score reflects the degree of atypia in a lesion and indicates the risk of skin lesion malignancy. For each diagnostic result (LIPS score) generated, the corresponding Negative Predictive Value (NPV) and Positive Predictive Value (PPV) derived from Speclipse’s clinical study is also presented. These clinically meaningful parameters can help physicians obtain more information about the skin lesion and decide on the best course of the action.

Tracking the clinical history of skin lesions
Tracking the clinical history of a skin lesion is as important as the patient’s medical history in terms of skin cancer diagnosis and treatment. Spectra-Scope® provides a platform to record a substantial amount of lesion information, including the location of the lesion, its LIPS score, and the corresponding predictive diagnostic values, as well as patient data. The information of the skin lesions previously assessed with Spectra-Scope® is well organized and stored so that physicians can easily understand the clinical history of the lesion.

Product Videos and features


Published Studies

Clinically proven by 7,254 spectral data collected from multi-site clinics

Multi-site clinical studies guarantee the clinical efficacy of Spectra-Scope®. A total of 364 patients were recruited for three different study sites in Newcastle Skin Check (Charlestown, Australia), Eastern Suburb Dermatology (Bondi Junction, Australia), and Skin Cancer & cosmetic clinic (Neural Nay, Australia). 2,088 data from 348 skin cancer cases, and 5,166 spectral data from 861 benign lesions were used to validate its sensitivity and specificity. The first result was 95.4% sensitivity and 84.7% specificity, which is significantly superior to the visual screening performed by trained physicians. The outcome improved after completing an in-depth neural network training for the Spectra-Scope® with additional 6,654 spectral data, resulting in 97.6% sensitivity and 86.2% specificity. These results show that Spectra-Scope is a clinically proven skin cancer diagnostic system, and the resulting data was published in one of the most renowned medical journals and congress

Real-time, non-invasive, in-vivo skin cancer diagnostics based on laser spectroscopy and machine learning algorithms using aesthetic lasers

Sung Hyun Pyun, Wanki Min, Saleem Loghdey
Speclipse, Inc., Sunnyvale, CA; Integrated Specialist Healthcare, Miranda, NSW, Australia


Clinical Assessment of a real-time, non-invasive, in-vivo skin cancer diagnostic device based on laser spectroscopy and deep learning algorithm using aesthetic lasers

Girish S. Munavalli, Boncheol L. Goo, Chang-Hun Hun, Wanki Min, Sung Hyung Pyun Dermatology, Laser, and Vein Specialist of the Caroolinas, PLLC, Charlotte, NC; Speclipse, Inc. Sunnyvale, CA; Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea

Clinical assessment of a real time, high performance skin cancer diagnostic device based on laser induced plasma spectroscopy and deep learning algorithm

Girish S. Munavalli, Boncheol L. Goo, Chang-Hun Hun, Wanki Min, Sung Hyung Pyun Dermatology, Laser, and Vein Specialist of the Caroolinas, PLLC, Charlotte, NC; Speclipse, Inc. Sunnyvale, CA; Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea


Girish S. Munavalli, MD, MHS, FACMS
Dermatology, Laser & Vein Specialists of the Carolinas
Charlotte, North Carolina, USA

“As a practicing dermatologist, skin biopsies are a commonly used diagnostic test in our clinic and medical clinic around the world to confirm a high index of clinical suspicion regarding skin cancer. In addition to being invasive, skin biopsies and the corresponding pathologic evaluation are performed at considerable expense to the patient and the health care system. Spectra-Scope is a painless, rapid, and reliable method for the diagnosis of suspicious lesions at the point of care. Using cutting edge technology and the power of algorithmic machine learning, Spectra-Scope can pinpoint the probability of a malignant vs. benign lesion within minutes, sparing the patient the pain of a biopsy and dramatically lessening the angst of waiting days to weeks for the formal pathology report.  We found the Spectra-Scope to perform remarkably well in predicting the likelihood of a malignant lesion immediately at the patient bedside, and in many instances, providing an accurate histologic diagnosis.”

Dr Samuel Seit, MBBS(UNSW), Dip Pr Derm Distinction (Cardiff), Dip Laser Surg(ACCS), FRACGP, FCPCA, FASLMS

The Skin Cancer & Cosmetic Clinic  Neutral bay, New South Wales, Australia

“… Spectra-scope gives a very quick idea whether decision is to biopsy a lesion, or even to go cut it off …”

Boncheol Leo Goo, MD

Board-certified Dermatologist / Mohs micrographic surgeon
Naeum Skin Clinic

“… Although skin biopsy is the gold standard, still it is an invasive procedure and when the patients repeatedly need regular follow-up tests, they can be huge burden…. Spectra-scope is so impressive not only for the caregivers, but also to the patients by it’s a painless, rapid, and reliable method for the diagnosis of suspicious lesions, in a real-time manner …”

Chat Now